Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Other illness

• History of clinically significant Central Nervous System disease or neurological disorders
• History of confirmed Progressive Multifocal Leukoencephalopathy or neurological symptoms consistent
• Active clinically significant systemic bacterial, viral, parasitic or fungal infections
• Active, chronic disease of the immune system other than MS
• Severe cardiac disease or significant findings on the ECG
• History of life-threatening infusion or injection reaction related to ocrelizumab

Lab values

• Participants not adequately controlled on ocrelizumab (CD19+ B-cell count ≥10 cells/µL at screening)
  • Other inclusion and exclusion criteria may apply

Other

• Diagnosis of primary progressive multiple sclerosis (PPMS) according to the revised 2017 McDonald criteria
• Participant who is unable to undergo MRI scans

• Male or female aged 40 to 70 years (inclusive)
• Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
• Treated with ocrelizumab according to routine clinical practice and at standard dose
• Neurologically stable within 30 days
• Suitable to be switched to remibrutinib based on physician judgement or patient preference